A large cohort study from 2019 by Korzenik J et al., which included 17,018 participants under anti-TNF alpha agents for other autoimmune diseases other than IBD, aimed to assess the risk of developing either CD or UC [36]. This evidence concerns the gene TNF and inflammatory bowel disease.